ストックスクリーナーアプリを入手
31.03
5.76%
1.69
アフターアワーズ：
31.03
前日終値:
$29.34
開ける：
$29.5
24時間の取引高:
475.68K
Relative Volume:
0.67
時価総額：
$1.93B
収益：
$32.08M
当期純損益:
$-169.77M
株価収益率:
-10.92
EPS:
-2.8418
ネットキャッシュフロー:
$-147.70M
1週間 パフォーマンス:
+3.57%
1か月 パフォーマンス:
-8.82%
6か月 パフォーマンス:
-0.58%
1年 パフォーマンス:
+231.52%
1日の値動き範囲:
$29.39
$31.13
1週間の範囲:
$29.18
$31.13
52週間の値動き範囲:
$9.09
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Compare STOK vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
31.03 | 1.83B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-02-05 | 開始されました | Guggenheim | Buy |
| 2026-01-05 | 再開されました | Chardan Capital Markets | Buy |
| 2025-07-18 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
| 2024-10-14 | 再開されました | Leerink Partners | Outperform |
| 2024-03-26 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-07-25 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 再開されました | Canaccord Genuity | Buy |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-10-24 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 開始されました | Jefferies | Buy |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-11-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 開始されました | UBS | Neutral |
| 2021-05-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-15 | 再開されました | H.C. Wainwright | Buy |
| 2020-12-11 | 繰り返されました | Needham | Buy |
| 2020-10-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-09-29 | 開始されました | Needham | Buy |
| 2019-12-18 | 開始されました | Wedbush | Outperform |
| 2019-11-12 | 開始されました | BTIG Research | Buy |
| 2019-10-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-15 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Cowen | Outperform |
| 2019-07-15 | 開始されました | Credit Suisse | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
すべてを表示
Stoke Therapeutics Inc (STOK) 最新ニュース
UBS Group AG Decreases Stock Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Nathan Lee Starts New Role as Vice President, Commercial Manufacturing at Stoke Therapeutics - hrtoday.in
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - TradingView
Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed - simplywall.st
Zorevunersen tied to long-term benefits in Dravet syndrome - Dravet Syndrome News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 18, 2026 - BioSpace
Lynx1 (STOK) files 13G/A reporting 4.76M shares, 8.1% stake - Stock Titan
Technical Reactions to STOK Trends in Macro Strategies - Stock Traders Daily
Stoke Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Stoke Therapeutics (STOK): Analyst Ratings and Price Target Upda - GuruFocus
Lynx1 Capital discloses 4.12M shares of Stoke Therapeutics (STOK) - Stock Titan
Redmile Group reports 4.16M shares in Stoke Therapeutics (STOK) - Stock Titan
TD Bank (NASDAQ: STOK) reports 3.18M shares, 5.4% stake - Stock Titan
RTW Funds and R. Wong report 9.99% stake in Stoke Therapeutics (STOK) - Stock Titan
Wellington affiliates hold 3.1M shares in Stoke Therapeutics (STOK) - Stock Titan
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate - Moomoo
HC Wainwright Analysts Boost Earnings Estimates for STOK - MarketBeat
Stoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balance - MSN
Stoke Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:STOK) 2026-05-11 - Seeking Alpha
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Stoke Therapeutics' (STOK) "Buy" Rating Reiterated at BTIG Research - MarketBeat
STOK Reiterates by BTIG -- Price Target Maintained at $39.00 - GuruFocus
Guggenheim Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60 - Moomoo
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $38 to $60 - Moomoo
Stoke Therapeutics Q1 Earnings Call Highlights - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Stoke Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates - BioSpace
Transcript : Stoke Therapeutics, Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
Stoke Therapeutics Q1 2026 slides show zorevunersen Phase 3 progress By Investing.com - Investing.com Canada
Earnings call transcript: Stoke Therapeutics Q1 2026 results show mixed performance By Investing.com - Investing.com South Africa
Earnings call transcript: Stoke Therapeutics Q1 2026 results show mixed performance - Investing.com Nigeria
Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion - ChartMill
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Why Stoke Therapeutics Stock Is Sliding Hard Today - TipRanks
STOKE THERAPEUTICS Q1 EPS USD -0.79 - Moomoo
Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q1 Revenue $6.2M, vs. FactSet Est of $6.5M - marketscreener.com
Stoke Therapeutics (Nasdaq: STOK) Q1 2026 loss, zorevunersen data and cash runway to 2028 - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) swings to Q1 2026 loss as Biogen upfront revenue rolls off - Stock Titan
Stoke Therapeutics faces earnings test after revenue miss By Investing.com - Investing.com Nigeria
Stoke Therapeutics faces earnings test after revenue miss - Investing.com UK
Trading the Move, Not the Narrative: (STOK) Edition - Stock Traders Daily
Privium Fund Management B.V. Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Stoke Therapeutics (STOK) CMO sells 2,243 shares in open-market trade - Stock Titan
Stoke Therapeutics Inc (STOK) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):